J.P. Morgan Securities LLC
383 Madison Avenue
New York, New York 10179
Cowen and Company, LLC
599 Lexington Avenue
New York, New York 10022
Piper Jaffray & Co.
345 Park Avenue, Suite 1200
New York, NY 10154
October 28, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Sonia Bednarowski |
Re: Oyster Point Pharma, Inc.
Registration Statement on FormS-1
FileNo. 333-234104
Acceleration Request
Requested Date: October 30, 2019
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Oyster Point Pharma, Inc. (the “Company”) for acceleration of the effective date of the above-referenced Registration Statement, requesting effectiveness as of 4:00 P.M., Eastern Time, on October 30, 2019, or as soon thereafter as practicable, or at such later time as the Company or its outside counsel, Wilson Sonsini Goodrich & Rosati, P.C., may request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that between October 21, 2019 through the date hereof we have distributed approximately 2,290 copies of the Company’s preliminary prospectus dated October 21, 2019 to prospectus underwriters, dealers, institutional investors and others.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]